High HDL-C*
(n=152)		 Low HDL-C†
(n=179)		 p value
Gender n (%)
Female
Male
66 (43.4)
86 (56.6)
83 (46.4)
96 (53.6)
0.5912
Ethnicity n (%)
Caucasian
No Caucasian		 102 (67.1)
50 (32.9)		 108 (60.3)
71 (39.7)		 0.2025
Age (years) 40.0
(32.0-46.0)		 40.0
(34.0-46.0)		 0.8785
Body mass index (Kg/cm2) 23.6
(21.2-26.3)		 24.4
(21.7-27.0)		 0.2827
Waist circumference (cm) 90.0
(84.2-98.0)		 90.0
(84.0-96.0)		 0.3801
HAART n (%)
Yes
No		 107 (70.4)
45 (29.6)		 129 (72.1)
50 (27.9)		 0.8331
PIs n (%)
Yes
No		 67 (44.1)
85 (55.9)		 92 (51.4)
87 (48.6)		 0.2234
NRTIs n (%)
Yes
No		 106 (69.7)
46 (30.3)		 128 (71.5)
51 (28.5)		 0.8168
NNRTIs n (%)
Yes
No		 42 (27.6)
110 (72.4)		 41 (22.9)
138 (77.1)		 0.3890
Genotypic analysis n (%)
P2P2
P1P1+P1P2		 18 (11.8)
134 (88.2)		 10 (5.6)
169 (94.4)		 0.0398**
Chi-square test with Yates’ correction. Mann-Whitney test. Data are expressed median (25%-75%). *HDL-C: high-density lipoprotein cholesterol was considered HIGH: men
≥ 40 mg/dL and women ≥ 50 mg/dL; †HDL-C: high-density lipoprotein cholesterol was considered LOW: men<40 mg/dL and women<50 mg/dL; PvuII LDLR polymorphism:
P1/P1: homozygous genotype for the P1 allele; P1/P2: heterozygous genotype with the P1 and P2 alleles; P2/P2: homozygous genotype for the P2 allele; HAART: highly
active antiretroviral therapy; PIs: Protease inhibitors; NRTI: nucleoside reverse transcriptase inhibitors; NNRTIs: non-nucleoside reverse transcriptase inhibitors
**OR: 0.3941 (CI 95%: 0.1715-0.9054)
Table 3: Demographic, genetic, clinical characteristics, and PvuII LDLR intron 15 polymorphism results of HIV-1-infected patients from Southern Brazil, according to the
serum high-density lipoprotein cholesterol (HDL-C) levels.
Goto home»